Herb-spreading moxibustion as an adjuvant treatment for chemotherapy-induced nausea and vomiting of spleen and stomach deficiency cold in gastric cancer: a randomized controlled trial.
10.13703/j.0255-2930.20241220-0001
- Author:
Zhongting ZHAO
1
;
Xiaohua WANG
1
;
Jie CAO
1
;
Fan FAN
1
Author Information
1. College of Acupuncture-Moxibustion and Tuina, Gansu University of CM, Lanzhou 730101, China.
- Publication Type:English Abstract
- Keywords:
chemotherapy-induced nausea and vomiting (CINV);
gastric cancer;
herb-spreading moxibustion;
randomized controlled trial (RCT);
spleen and stomach deficiency cold
- MeSH:
Humans;
Moxibustion;
Male;
Female;
Middle Aged;
Stomach Neoplasms/drug therapy*;
Nausea/physiopathology*;
Vomiting/physiopathology*;
Aged;
Adult;
Acupuncture Points;
Antineoplastic Agents/therapeutic use*;
Drugs, Chinese Herbal/administration & dosage*;
Spleen/drug effects*;
Stomach/drug effects*
- From:
Chinese Acupuncture & Moxibustion
2025;45(12):1723-1729
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the clinical efficacy of herb-spreading moxibustion as an adjuvant treatment for chemotherapy-induced nausea and vomiting (CINV) of spleen and stomach deficiency cold in gastric cancer.
METHODS:Seventy-six patients with CINV of spleen and stomach deficiency cold in gastric cancer were randomly divided into an observation group (38 cases, 1 case was discontinued, 1 case dropped out) and a control group (38 cases, 1 case was discontinued). The patients in both groups were treated with cisplatin+tigio regimen chemotherapy, and were treated with basic anti-nausea drugs on the 1st to 3rd day of chemotherapy. The observation group was treated with herb-spreading moxibustion at Zhongwan (CV12) acupoint area (covering from Shangwan [CV13] to Shenque [CV8] of the conception vessel, and from both sides to the kidney meridian of foot-shaoyin). The herb was selected as Fuzi Lizhong decoction, once a day, about 50 min each time, with 3 consecutive days as one treatment course, with an interval of 1 day between each course, for a total of 3 treatment courses. The grading of nausea and vomiting degree in the two groups were recorded on the 1st, 3rd, 7th and 14th days of chemotherapy. Karnofsky performance status (KPS) score in the two groups was observed before treatment and on the 1st, 3rd, 7th and 14th days of chemotherapy. The TCM symptom grading and TCM syndrome score of the two groups before and after treatment were compared, and the clinical efficacy and safety of the two groups were evaluated.
RESULTS:On the 7th and 14th days of chemotherapy, the grading of nausea degree in the observation group was lower than that in the control group (P<0.05). On the 3rd, 7th and 14th days of chemotherapy, the grading of vomiting degree in the observation group was lower than that in the control group (P<0.05, P<0.01). Compared before treatment, the KPS scores of the two groups on the 1st day of chemotherapy and the control group on the 7th day of chemotherapy were decreased (P<0.05, P<0.01), and the KPS scores of the observation group on the 7th day of chemotherapy and the two groups on the 14th day of chemotherapy were increased (P<0.01). On the 7th and 14th days of chemotherapy, the KPS scores of the observation group were higher than those of the control group (P<0.01). After treatment, the each item grading of TCM symptom in the two groups was better than that before treatment (P<0.01), except for loose stool, the each item grading of TCM symptom in the observation group was better than that in the control group (P<0.05, P<0.01). After treatment, the scores of TCM syndrome in the two groups were lower than those before treatment (P<0.01), and the score in the observation group was lower than that in the control group (P<0.01). The obvious effective rate of the observation group was 58.3% (21/36), which was higher than 24.3% (9/37) of the control group (P<0.01). No adverse events occurred in both groups.
CONCLUSION:Herb-spreading moxibustion as an adjuvant treatment for CINV of spleen and stomach deficiency cold in gastric cancer can effectively relieve nausea and vomiting, and improve the symptoms of TCM, and improve the quality of life of patients. The clinical efficacy is satisfactory and the safety is good.
